168 related articles for article (PubMed ID: 16182830)
21. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
Basse G; Esposito L; Mengelle C; Kamar N; Ribes D; Lavayssière L; Pillet A; Suc B; Barange K; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2339-41. PubMed ID: 16980084
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous pancreas-kidney transplantation: analysis of rejection.
Malaise J; Arbogast H; Illner WD; Tarabichi A; Dieterle C; Landgraf R; Land W; Van Ophem D; Squifflet JP;
Transplant Proc; 2005; 37(6):2856-8. PubMed ID: 16182833
[TBL] [Abstract][Full Text] [Related]
23. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
24. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus infection in renal transplant recipients.
Carstens J; Andersen HK; Spencer E; Madsen M
Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
[TBL] [Abstract][Full Text] [Related]
26. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
Potena L; Holweg CT; Chin C; Luikart H; Weisshaar D; Narasimhan B; Fearon WF; Lewis DB; Cooke JP; Mocarski ES; Valantine HA
Transplantation; 2006 Aug; 82(3):398-405. PubMed ID: 16906040
[TBL] [Abstract][Full Text] [Related]
27. The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study).
Abou-Ayache R; Büchler M; Le Pogamp P; Westeel PF; Le Meur Y; Etienne I; Hurault de Ligny B; Toupance O; Caillard S; Sinnasse-Raymond G; Touchard G
Transplant Proc; 2011 Sep; 43(7):2630-5. PubMed ID: 21911136
[TBL] [Abstract][Full Text] [Related]
28. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus antibody status and kidney transplantation.
Terasaki PI; Yuge J; Cecka JM; Gjertson DW
Clin Transpl; 1994; ():509-18. PubMed ID: 7547579
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous pancreas-kidney transplantation in a large multicenter study: surgical complications.
Malaise J; Steurer W; Koenigsrainer A; Mark W; Margreiter R; Van Ophem D; Mourad M; Squifflet JP;
Transplant Proc; 2005; 37(6):2859-60. PubMed ID: 16182834
[TBL] [Abstract][Full Text] [Related]
31. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
Shah AP; Chen JM; Fridell JA
Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
[TBL] [Abstract][Full Text] [Related]
32. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
Varga M; Rajczy K; Telkes G; Hídvégi M; Péter A; Remport A; Korbonits M; Fazakas J; Toronyi E; Sárváry E; Kóbori L; Járay J
Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066
[TBL] [Abstract][Full Text] [Related]
33. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
34. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
[TBL] [Abstract][Full Text] [Related]
35. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus infection of the graft duodenum and urinary bladder after simultaneous pancreas-kidney transplantation.
Jang HJ; Kim SC; Cho YP; Kim YH; Han MS; Han DJ
Transplant Proc; 2004 Sep; 36(7):2200-2. PubMed ID: 15518799
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
38. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
[TBL] [Abstract][Full Text] [Related]
39. Infectious complications after simultaneous pancreas-kidney transplantation.
Michalak G; Kwiatkowski A; Bieniasz M; Meszaros J; Czerwinski J; Wszola M; Nosek R; Ostrowski K; Chmura A; Danielewicz R; Lisik W; Adadynski L; Fesołowicz S; Dobrowolska A; Durlik M; Rowiñski W
Transplant Proc; 2005 Oct; 37(8):3560-3. PubMed ID: 16298661
[TBL] [Abstract][Full Text] [Related]
40. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients.
Renoult E; Clermont MJ; Phan V; Buteau C; Alfieri C; Tapiero B
Pediatr Transplant; 2008 Jun; 12(4):420-5. PubMed ID: 18466427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
